Clinical TrialsEndocrine Response in Women With Invasive Lobular Breast Cancer Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ Research Papers / Posters
Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional seriesWe are interested in understanding the distribution and the clinical significance of ER/PR hormone receptor positivity in early-stage ILC. Overall, we know that ILC is typically regarded as strongly ER and PR positive and there is very little data that exists evaluating the spectrum of hormone receptor positivity in ILC. Using a single institution prospectively maintained ILC database, we evaluated patient characteristics, tumor features, and disease-free survival of patients based on different levels of ER and PR receptor positivity. Self-identified race and Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and event free survivalA recent analysis of the SEER database showed that racial/ethnic identity is associated with worse outcomes in those with ILC. We wanted to validate these findings in our institutional database of ILC patients and investigate whether including socioeconomic factors, measured using the Area Deprivation Index (ADI), would influence the associations between race and outcomes. HER2-low status in early stage ILCThe concept of HER2-low breast cancer has been proposed as a potential treatment target for breast cancers previously considered HER2-negative. In recent clinical trials, patients with HER2-low status have benefited from new therapeutic compounds that target HER2. However, the clinical implications of HER2-low status in invasive lobular carcinoma (ILC) has not been explored before. In this study we looked at survival outcomes and treatment characteristics of patients with stage I-III ILC based on HER2 status. | |